MOLECULAR PARTNERS TO PRESENT AT THE MORGAN STANLEY GLOBAL HEALTHCHARE CONFERENCE IN NEW YORK Mittwoch, 07. September 2016 - 10:02
 | ||||||||||||||||||
| Media Release (PDF) | ||||||||||||||||||
MOLECULAR PARTNERS TO PRESENT AT THE MORGAN STANLEY GLOBAL HEALTHCHARE CONFERENCE IN NEW YORK | ||||||||||||||||||
Zurich-Schlieren, September 07, 2016. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company that is developing a new, class of therapies known as DARPins, today announced that Dr. Christian Zahnd, CEO and Andreas Emmenegger, CFO of Molecular Partners will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Monday, September 12, 2016 at 5:25 PM Eastern Time (11:25 PM CET). | ||||||||||||||||||
The presentation will be available for viewing via live webcast and can be accessed on the day through this link. A replay of the webcast will be made available on the company's websitewww.molecularpartners.com under the Investors section. The replay will be available for 180 days following the presentation. | ||||||||||||||||||
About Molecular Partners AG Molecular Partners AG is a clinical-stage biopharmaceutical company that is developing a new, class of therapies known as DARPins. DARPins are potent, specific, and versatile small-protein therapies, which have the potential to offer benefits over conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin®technology has the potential to offer a multi-specific approach to treatment, which enables DARPins to target multiple pathways, or multiple epitopes on a single target to achieve substantial patient benefit. DARPins have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders.
Molecular Partners has four compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology. The company has ongoing research and development partnerships with leading pharmaceutical companies, including Allergan and Janssen, and is backed by established biotech investors. For more information regarding Molecular Partners AG, go to:www.molecularpartners.com.
For further details, please contact:
|